Known Interactions Between Kratom and Ibogaine
The concurrent use of kratom and ibogaine is not recommended and should be avoided due to serious safety concerns, including overlapping cardiac toxicity (particularly QTc prolongation from ibogaine), complex opioid receptor interactions, and potential for serotonergic effects that could lead to life-threatening complications.
Critical Safety Concerns
Kratom-Specific Risks
Kratom is explicitly not recommended for use by the Society for Perioperative Assessment and Quality Improvement (SPAQI) due to potential for serious adverse effects 1. The substance has:
- Opioid agonist properties with withdrawal potential when taking more than 5-15 g per day
- Stimulant-like properties at lower doses
- Risk of neurologic effects including seizures with chronic use
- The FDA has issued warnings against its use 1
Kratom's pharmacology is complex, affecting multiple neurotransmitter systems including opioid, noradrenergic, serotonergic, and dopaminergic pathways 2. This broad receptor activity creates substantial potential for drug interactions 3.
Ibogaine-Specific Risks
Ibogaine carries significant cardiac toxicity with a narrow therapeutic margin 4. Key concerns include:
- Dose-dependent QTc prolongation demonstrated in randomized trials (60-180 mg doses in opioid-dependent patients) 4
- Neurologic, psychiatric, and cardiac adverse events
- Fatalities have occurred, particularly in patients with medical and substance use comorbidities 4
Why Combined Use Is Dangerous
Overlapping Pharmacological Effects
Cardiac Risk Amplification: Ibogaine's documented QTc prolongation combined with kratom's cardiovascular effects (which can include sympathetic hyperactivity) creates compounded cardiac risk
Opioid Receptor Interactions: Both substances interact with opioid receptors—kratom as an agonist and ibogaine in the context of opioid withdrawal treatment. This creates unpredictable receptor dynamics that could precipitate withdrawal, excessive sedation, or respiratory depression
Serotonergic Activity: Both substances have serotonergic properties 2, raising concern for serotonin syndrome when combined, particularly given kratom's multi-system neurotransmitter effects
Drug Metabolism Concerns: Kratom alkaloids can affect pharmacokinetic processes of concurrent medications 3, potentially altering ibogaine metabolism and increasing toxicity risk
Clinical Recommendations
If a patient is using kratom and considering ibogaine treatment:
- Discontinue kratom with appropriate tapering if taking >5-15 g daily to avoid withdrawal 1
- Allow a minimum 2-week washout period before ibogaine administration, consistent with SPAQI guidelines for supplements with multiple drug interactions 1
- Screen for cardiac risk factors and obtain baseline ECG given ibogaine's QTc effects
- Monitor for withdrawal symptoms during kratom discontinuation
Common Pitfalls to Avoid:
- Do not assume kratom is "just a supplement"—it has genuine opioid activity requiring medical management
- Do not proceed with ibogaine without full disclosure of kratom use, as this significantly increases risk
- Do not underestimate withdrawal potential from kratom cessation in chronic users
Evidence Quality Note
While both substances are being investigated for opioid use disorder treatment 5, the evidence base consists primarily of small observational studies and animal research. The three available randomized controlled trials for ibogaine 4 demonstrate safety concerns but lack data on kratom co-administration. No studies directly examine the kratom-ibogaine interaction, making clinical recommendations based on known individual risks and pharmacological mechanisms.